Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.
about
The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinomaAssociation of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.Cellular effects induced by 17-β-estradiol to reduce the survival of renal cell carcinoma cells.Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC).Dual modulation of MCL-1 and mTOR determines the response to sunitinib.Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatmentPrimary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science.Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor.Emerging antiangiogenics for renal cancer.Strategies to overcome therapeutic resistance in renal cell carcinoma.Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma.Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma.Efficacy of fourth-line targeted therapy in patients with metastatic renal cell carcinoma: a retrospective analysis.Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors.Sunitinib resistance in renal cell carcinoma.Maslinic Acid Inhibits Proliferation of Renal Cell Carcinoma Cell Lines and Suppresses Angiogenesis of Endothelial Cells.Glutathione-S-transferase-pi (GST-pi) expression in renal cell carcinoma.The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma.miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell CarcinomaCharacterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells
P2860
Q35523317-DA48F850-0B81-4364-89ED-0B307E225FD0Q35995721-5372A89B-B033-4485-A04A-67B1ADCE943CQ37185773-53C3221C-9343-462F-92DD-32A534653BE2Q37294496-CC5B034A-4B51-4F23-B7FB-6389617DD427Q37385255-61251AA1-9A23-47A6-928F-24D748B38097Q37544978-D465598B-55A6-4B73-892F-0403AC33BEA6Q38025626-9711BE25-BF8E-4157-9C20-D65741791B56Q38062554-242D7A93-FC8A-450E-BA03-CBC6B8E3E250Q38110320-309EC28A-0E12-4805-A3A2-1C6932016091Q38166015-818D9456-3532-4836-9858-6D3DC338E58BQ39089402-FF180F80-7360-4447-AF2B-484873E47F26Q40826012-F963A391-02F3-4DF9-BDB6-4E975DDFF631Q41145898-A44C0C2C-50C5-4332-B00F-E415717EA382Q48279396-8CC98F6B-A1B7-4592-9A74-F112179AAA87Q49184931-7FB72092-DE5F-4FAF-82CA-748A0F2628EEQ51763292-352EC971-68C8-41F4-A3E7-9A1A87B1B4ACQ53743976-725D6CAB-D355-4F65-9715-4CFFD7B37D99Q54857864-35C1E7E0-8EC6-41D2-BF34-ACC8A39A05C4Q55026900-CAC7D248-D7BD-46CC-BF6F-0A09B7182E2BQ58753441-386C5C31-499A-4539-AA1B-960CF4C1EC8CQ58790703-CE4681B5-F9C3-47BC-AB13-20D60E9490CE
P2860
Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Intrinsic resistance to tyrosi ...... tastatic renal cell carcinoma.
@ast
Intrinsic resistance to tyrosi ...... tastatic renal cell carcinoma.
@en
type
label
Intrinsic resistance to tyrosi ...... tastatic renal cell carcinoma.
@ast
Intrinsic resistance to tyrosi ...... tastatic renal cell carcinoma.
@en
prefLabel
Intrinsic resistance to tyrosi ...... tastatic renal cell carcinoma.
@ast
Intrinsic resistance to tyrosi ...... tastatic renal cell carcinoma.
@en
P2093
P2860
P356
P1433
P1476
Intrinsic resistance to tyrosi ...... etastatic renal cell carcinoma
@en
P2093
Ahmed Magheli
Carsten Kempkensteffen
Christoph Seidel
Jonas Busch
Kurt Miller
Lisa Weinkauf
Stefan Hinz
Steffen Weikert
Viktor Grünwald
P2860
P2888
P356
10.1186/1471-2407-11-295
P407
P50
P577
2011-07-14T00:00:00Z
P5875
P6179
1021293794